NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781

RecruitingPhase 4

Sponsor: Janssen Research & Development, LLC

Conditions: Multiple Myeloma

Interventions: Cilta-cel

Countries: United States, Belgium, China, France, Israel, Japan, Netherlands, Spain

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
* Participants who have provided informed consent for this study

Locations (50)

Phoenix, Arizona, United States
Duarte, California, United States
San Francisco, California, United States
Stanford, California, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Westwood, Kansas, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Rochester, Minnesota, United States
St Louis, Missouri, United States
Hackensack, New Jersey, United States
New Brunswick, New Jersey, United States
Buffalo, New York, United States
New York, New York, United States
New York, New York, United States
The Bronx, New York, United States
Charlotte, North Carolina, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Milwaukee, Wisconsin, United States
Ghent, Belgium
Leuven, Belgium
+ 20 more on CT.gov